AAV Gene Therapy: Viral Vectors, Capsid Design & Clinical Applications

Added:

Non-Viral Gene Delivery Platforms: Synthetic Vectors and Lipid Nanoparticles

While AAV vectors are the current standard for in vivo gene therapy, they face significant limitations, including a strict cargo capacity of under 5 kilobases, high prevalence of pre-existing neutralizing antibodies in the human population, and severe dose-dependent immunogenicity and hepatotoxicity. A powerful alternative perspective champions non-viral delivery systems, such as lipid nanoparticles (LNPs), polymeric nanoparticles, and ligand-conjugated oligonucleotides. Proponents of non-viral platforms argue that synthetic vectors offer a safer, more scalable, and cost-effective paradigm. Unlike AAV, synthetic vectors do not trigger pre-existing immunity, allowing for crucial repeat dosing (re-dosability), and they can transport much larger genetic payloads (including entire gene-editing complexes like CRISPR-Cas9). This counterpoint suggests that the future of genetic medicine lies not in engineering complex viral capsids, but in advancing synthetic, biomimetic materials that bypass the safety and manufacturing bottlenecks of viral-based gene therapies.

Basic molecular biology principles, including the central dogma of genetics (DNA to RNA to protein) and gene expression regulation (promoters, enhancers, and polyadenylation).
Fundamentals of virology, specifically the structural classification of viruses, capsid assembly, and viral genome replication cycles.
Recombinant DNA technology techniques, such as plasmid design, molecular cloning, and transfection methods in mammalian host cells.
General concepts of gene therapy, including the difference between in vivo and ex vivo genetic modification strategies.
Advanced capsid engineering techniques, including directed evolution, rational design, and machine learning models for improving tissue tropism and target specificity.
Immunogenicity and host immune barriers, focusing on pre-existing neutralizing antibodies to AAV and strategies for immune evasion.
Regulatory pathways and quality control standards for scaling up AAV manufacturing under Good Manufacturing Practice (GMP) guidelines.
The integration of gene-editing technologies, such as CRISPR/Cas9 and base editors, with AAV-mediated delivery systems for precise in vivo therapeutics.
80K views827likes30:01@ASGCTOriginal Release: 2019-11-27

Adeno-associated virus (AAV) is a non-pathogenic parvovirus that requires helper viruses for replication; recombinant AAV vectors are created by separating the viral genome into ITR-flanked transgenes and trans-acting rep/cap genes, enabling flexible therapeutic gene delivery with packaging capacity around 4.7 kb, where self-complementary designs enhance expression efficiency by providing immediate double-stranded templates.